Synthetic Design Lab is advancing a proprietary SYNTHBODY™ therapeutic platform engineered to optimize targeted payload delivery at least tenfold compared with current ADCs. The company says the platform aims to improve efficacy, safety, and versatility of ADCs across a broader range of cancer targets. Leadership includes founder and CEO Daniel S. Chen, M.D., Ph.D., a physician‑scientist who previously led clinical development for atezolizumab (TECENTRIQ®) at Genentech, and co‑founder and CSO Ramesh Baliga, Ph.D. Synthetic Design Lab positions its platform at the intersection of protein engineering, synthetic biology, and AI to build novel ADC constructs. The company expects to move its first therapeutic into clinical trials next year and expects to enter the clinic in 2026. It emerged from stealth with $20 million in seed financing to advance its pipeline.

Total raised

$20M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025